Crispr Therapeutics AG vs Vanguard Growth Index Fund ETF — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Vanguard Growth Index Fund ETF trades at $88.96. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | VUG | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $90.29 |
52-Week Low | $44.34 | $70.00 |
Enterprise Value | $3.65B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →